Skip to main content

X-linked Myotubular Myopathy

2
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
1100%
+ 2 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
3 programs
1
1
Resamirigene bilparvovecPhase 2/3Gene Therapy1 trial
ASP2957Phase 1/22 trials
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) SubjectsN/A1 trial
Active Trials
NCT02704273Completed34Est. Sep 2019
NCT07876804Not Yet Recruiting9Est. Jul 2032
NCT07052929Recruiting9Est. Oct 2027
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstellasResamirigene bilparvovec
AstellasASP2957
AstellasASP2957
AstellasA Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

Clinical Trials (4)

Total enrollment: 79 patients across 4 trials

NCT03199469AstellasResamirigene bilparvovec

A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)

Start: Aug 2017Est. completion: Mar 203027 patients
Phase 2/3Active Not Recruiting

A Long-term Follow-up Study in Male Participants With X-linked Myotubular Myopathy Treated With ASP2957

Start: Oct 2026Est. completion: Jul 20329 patients
Phase 1/2Not Yet Recruiting

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Start: Dec 2025Est. completion: Oct 20279 patients
Phase 1/2Recruiting
NCT02704273AstellasA Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

Start: Jul 2016Est. completion: Sep 201934 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 79 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.